PMID- 36479934
OWN - NLM
STAT- MEDLINE
DCOM- 20230324
LR  - 20230326
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 5
DP  - 2023 Mar
TI  - Survival trends for patients with retinoblastoma between 2000 and 2018: What has 
      changed?
PG  - 6318-6324
LID - 10.1002/cam4.5406 [doi]
AB  - INTRODUCTION: Retinoblastoma (RB) is the most common primary intraocular cancer 
      of childhood. Over the last few decades, a variety of techniques and treatment 
      modalities emerged that improved the survival and ocular salvage rate of patients 
      with RB. We investigated the relative survival trends of patients with RB from 
      2000 to 2018 by using the Surveillance, Epidemiology, and End Results (SEER) 
      database. DESIGN: Retrospective database review. METHODS: We extracted data from 
      SEER 18 from 2000 to 2018. All patients with clinically diagnosed RB during the 
      study period were included. We utilized SEER*Stat 8.3.9 and JPSurv software to 
      estimate relative 5- and 10-year survival rates and trends and generated 
      descriptive analyses with IBM SPSS. MAIN OUTCOME MEASURES: Patient survival rates 
      at 5- and 10-year after RB diagnosis. RESULTS: RB was diagnosed in 1479 patients 
      within the SEER 18 Program during our study period. The cohort comprised 776 
      (52.5%) males, 615 (41.6%) non-Hispanic whites, 487(32.9%) Hispanics, 1030 
      (69.6%) patients with unilateral disease, and 1087 (73.5%) patients with 
      localized disease. Relative survival trends at 5- and 10-year significantly 
      declined over the study periods (-0.42%, and -0.50% annually, respectively) but 
      the decline was not significant in unilateral and bilateral RB cases separately. 
      CONCLUSIONS: Five- and ten-year relative survival trends declined from 2000 to 
      2018 and were significantly decreasing. Further studies that include more 
      patients are needed to identify the factors contributing to reduced survival of 
      patients with RB over time.
CI  - (c) 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Abdelazeem, Basel
AU  - Abdelazeem B
AUID- ORCID: 0000-0002-2919-6196
AD  - McLaren Health Care, Flint/Michigan State University, Flint, Michigan, USA.
FAU - Abbas, Kirellos Said
AU  - Abbas KS
AUID- ORCID: 0000-0003-0339-9339
AD  - Faculty of Medicine, Alexandria University, Alexandria, Egypt.
FAU - Shehata, Joseph
AU  - Shehata J
AUID- ORCID: 0000-0002-3373-7047
AD  - Faculty of Medicine, Cairo University, Cairo, Egypt.
FAU - El-Shahat, Nahla Ahmed
AU  - El-Shahat NA
AD  - Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
FAU - Eltaras, Mennatullah Mohamed
AU  - Eltaras MM
AD  - Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
FAU - Qaddoumi, Ibrahim
AU  - Qaddoumi I
AD  - St. Jude Children Research Hospital, Memphis, Tennessee, USA.
FAU - Alfaar, Ahmad Samir
AU  - Alfaar AS
AUID- ORCID: 0000-0002-0930-4583
AD  - Ophthalmology Department, University of Um, Ulm, Germany.
AD  - Experimental Ophthalmology, Campus Virchow-Klinikum, Charite Universitatsmedizin 
      Berlin, Berlin, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221208
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - *Retinal Neoplasms/therapy
MH  - *Retinoblastoma/epidemiology/therapy
MH  - Retrospective Studies
MH  - SEER Program
MH  - Survival Rate
MH  - White People
MH  - Hispanic or Latino
PMC - PMC10028055
COIS- The authors declare no conflict of interest.
EDAT- 2022/12/09 06:00
MHDA- 2023/03/24 06:00
PMCR- 2022/12/08
CRDT- 2022/12/08 14:33
PHST- 2022/10/13 00:00 [revised]
PHST- 2022/03/26 00:00 [received]
PHST- 2022/10/24 00:00 [accepted]
PHST- 2022/12/09 06:00 [pubmed]
PHST- 2023/03/24 06:00 [medline]
PHST- 2022/12/08 14:33 [entrez]
PHST- 2022/12/08 00:00 [pmc-release]
AID - CAM45406 [pii]
AID - 10.1002/cam4.5406 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Mar;12(5):6318-6324. doi: 10.1002/cam4.5406. Epub 2022 Dec 8.